These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 33598874

  • 1. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
    Yang S, Lee LA, Sule N, Fowler A, Peachey G.
    Clin Pharmacokinet; 2021 Jul; 60(7):887-896. PubMed ID: 33598874
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID.
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
    Nakamura Y, Hozawa S, Sagara H, Ohbayashi H, Lee LA, Crawford J, Tamaoki J, Nishi T, Fowler A.
    Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
    [Abstract] [Full Text] [Related]

  • 5. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG.
    Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
    [Abstract] [Full Text] [Related]

  • 6. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA.
    Respir Res; 2018 Jan 25; 19(1):19. PubMed ID: 29370819
    [Abstract] [Full Text] [Related]

  • 7. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
    Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, Wise R, Lipson DA.
    Respir Res; 2020 Jun 05; 21(1):139. PubMed ID: 32503599
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep 05; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA.
    Ther Adv Respir Dis; 2020 Sep 05; 14():1753466620963021. PubMed ID: 33121372
    [No Abstract] [Full Text] [Related]

  • 10. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, Harvey C, Kaisermann MC, Lipson DA, Martin N, Sciurba F, Stiegler M, Zhu CQ, Bernstein D.
    Respir Res; 2020 May 29; 21(1):131. PubMed ID: 32471423
    [Abstract] [Full Text] [Related]

  • 11. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
    Bardsley S, Criner GJ, Halpin DMG, Han MK, Hanania NA, Hill D, Lange P, Lipson DA, Martinez FJ, Midwinter D, Siler TM, Singh D, Wise RA, van Zyl-Smit RN, Berkman N.
    Respir Med; 2022 Dec 29; 205():107040. PubMed ID: 36470149
    [Abstract] [Full Text] [Related]

  • 12. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA.
    Int J Chron Obstruct Pulmon Dis; 2019 Dec 29; 14():2849-2861. PubMed ID: 31839705
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA.
    Chest; 2021 Mar 29; 159(3):985-995. PubMed ID: 33031829
    [Abstract] [Full Text] [Related]

  • 15. Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management.
    Busse WW, Abbott CB, Germain G, Laliberté F, MacKnight SD, Jung Y, Duh MS, Averell CM.
    J Allergy Clin Immunol Pract; 2022 Nov 29; 10(11):2904-2913.e6. PubMed ID: 35752431
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.
    Brealey N, Gupta A, Renaux J, Mehta R, Allen A, Henderson A.
    Int J Clin Pharmacol Ther; 2015 Sep 29; 53(9):753-64. PubMed ID: 26227101
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
    Lipson DA, Birk R, Brealey N, Zhu CQ.
    Adv Ther; 2020 Dec 29; 37(12):4894-4909. PubMed ID: 33011864
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults.
    Li Y, Li H, Sheng Y, Du X, Yao Y, Luo X, Ma P.
    Clin Pharmacol Drug Dev; 2019 Aug 29; 8(6):721-733. PubMed ID: 30427594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.